
-
Regeneron Pharmaceuticals NasdaqGS:REGN Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Location: 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6707, United States | Website: https://www.regeneron.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
57.15B
Cash
8.349B
Avg Qtr Burn
N/A
Short % of Float
2.84%
Insider Ownership
1.90%
Institutional Own.
92.13%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Evkeeza (evinacumab) Details Homozygous familial hypercholesterolemia | Approved Update | |
EYLEA (aflibercept) Details Diabetic retinopathy | Approved Quarterly sales | |
Praluent® (alirocumab) Details Heterozygous familial hypercholesterolemia | Approved Quarterly sales | |
Dupixent Details Chronic obstructive pulmonary disease | Approved Quarterly sales | |
Libtayo® (cemiplimab) Details Non-small cell lung carcinoma, Cutaneous squamous cell carcinoma | Approved Quarterly sales | |
Kevzara (sarilumab) Details Polymyalgia rheumatica | Approved Quarterly sales | |
Veopoz™ (pozelimab-bbfg) Details Rare diseases, CD55-deficient protein-losing enteropathy , CHAPLE disease | Approved Quarterly sales | |
Dupixent® (dupilumab) (IL-4 IL-13) Details Chronic spontaneous urticaria | Approved Quarterly sales | |
Dupixent® (dupilumab) (IL-4 IL-13) Details Chronic rhinosinusitis with nasal polyps | Approved Quarterly sales | |
Dupixent® (dupilumab) (IL-4 IL-13) Details Eosinophilic Esophagitis | Approved Quarterly sales | |
Kevzara (sarilumab) Details Polyarticular juvenile idiopathic arthritis | Approved Quarterly sales | |
EYLEA (aflibercept) Details Retinopathy of prematurity | Approved Quarterly sales | |
EYLEA HD (aflibercept) Details Wet age-related macular degeneration , Diabetic macular edema | Approved Quarterly sales | |
EYLEA HD® (aflibercept) Injection Details Macular edema following retinal vein occlusion | PDUFA Approval decision | |
Odronextamab Details Follicular lymphoma, Diffuse large B cell lymphoma | PDUFA Approval decision | |
Linvoseltamab (BCMAXCD3) Details Blood cancer, Cancer, Multiple myeloma | PDUFA Approval decision | |
Dupixent® (dupilumab) Details Bullous pemphigoid | PDUFA Approval decision | |
Libtayo® (cemiplimab) Details Cutaneous squamous cell carcinoma | BLA Submission | |
Dupixent (dupilumab) Details Skin disease/disorder, Atopic dermatitis | Phase 3 Data readout | |
Itepekimab Details Chronic obstructive pulmonary disease | Phase 3 Data readout | |
REGN9933 (Factor XI antibody) Details Thrombosis | Phase 3 Initiation | |
Fianlimab + Libtayo® (cemiplimab) Details Advanced malignancies, Melanoma | Phase 2/3 Data readout | |
Fianlimab + Libtayo® (cemiplimab) Details Non-small cell lung carcinoma | Phase 2/3 Data readout | |
DB-OTO (AAV-based gene therapy) Details Hearing loss | Phase 1/2 Data readout | |
REGN5668 (targeting MUC16 and CD28) +Libtayo Details Cancer, Ovarian cancer | Phase 1 Data readout | |
Dupixent Details Chronic inducible urticaria | Failed Discontinued |